Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 6Breast 3Thoracic 2Gynecologic 2Head & Neck 1Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Stomach Neoplasms 2Ovarian Neoplasms 2Colorectal Neoplasms 2Breast Neoplasms 2Sarcoma 1Salivary Gland Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

pembrolizumab 39Nivolumab 13Cisplatin 12Paclitaxel 11Docetaxel 11Carboplatin 10atezolizumab 9Trastuzumab 9Gemcitabine 9Cyclophosphamide 8fludarabine 7Bevacizumab 7aldesleukin 6durvalumab 5Taxes 5Oxaliplatin 5Magnetic Resonance Spectroscopy 5Leucovorin 5Irinotecan 5Fluorouracil 5130-nm albumin-bound paclitaxel 5avelumab 4Specimen Handling 4Psychiatric Rehabilitation 4Ipilimumab 4Drug Therapy 4Cetuximab 4Capecitabine 4Albumin-Bound Paclitaxel 4tislelizumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Stomach Neoplasms × zanidatamab × Thoracic × Clear all
NCT06695845 2026-04-09

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

Jazz Pharmaceuticals

Phase 2 Recruiting
200 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Esophageal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT02892123 2024-11-27

Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers

Jazz Pharmaceuticals

Phase 1 Completed
279 enrolled
BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡